AMENDMENT NO. 3 TO CONSULTING SERVICES AGREEMENT
Exhibit 10.159
AMENDMENT NO. 3
TO
This Amendment (“Amendment No. 3”) is made between Vistagen Therapeutics, Inc., a Nevada corporation having an address at 000 Xxxxxxxx Xxxxxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000 (“Vistagen”), and XxxxXxxxxxx & Co. LLC, a Delaware limited liability company, having an address at 0000 Xxxxx Xxxxx, XX, Xxxxxxxxxx XX 00000 (“Consultant”), effective as of July 1, 2023.
WHEREAS, Xxxxxxxx and Consultant entered into a Consulting Services Agreement dated January 21, 2022, Amendment No. 1 to the Consulting Agreement dated June 1, 2022, and Amendment No. 2 to the Consulting Agreement dated January 1, 2023 (collectively, the “Agreement”); and
WHEREAS, the parties wish to amend the Agreement to extend its term.
Xxxxxxxx and Consultant, therefore, agree as follows:
AMENDMENT
1. |
The term of this Agreement shall be extended and continue until December 31, 2023. |
Except as expressly provided in this Amendment No. 3, the Agreement remains unchanged and in full force and effect.
[Remainder of page intentionally left blank]
Each party is signing this agreement with the party’s authorized signature.
AGREED TO: | AGREED TO: | |||
VISTAGEN THERAPEUTICS, INC. | XXXXXXXXXXX & CO., LLC | |||
By: | /s/ Xxxxx X. Xxxxx | By: | /s/ Xxxxxx XxxxXxxxxxx | |
Name: | Xxxxx X. Xxxxx, X.X. | Name: | Xxxxxxxx Xxxx XxxxXxxxxxx | |
Title: | Chief Executive Officer | Title: | Managing Director | |
Date: | June 22, 2023 | Date: | June 22, 2023 |